See today's BioWorld Asia
To read the full story, subscribe or sign in.

Inmagene raises $100M series C to initiate U.S.-China phase II trials of IL-17 inhibitor

June 22, 2021
By Elise Mak
Inmagene Biopharmaceuticals Co. Ltd. has raised $100 million in a series C financing to move its IL-17 inhibitor to phase II trials in the U.S. and China.
BioWorld Asia Financings Immune Series C China